Minireviews
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hematol. Feb 6, 2016; 5(1): 31-36
Published online Feb 6, 2016. doi: 10.5315/wjh.v5.i1.31
Advances and perspectives on cellular therapy in acquired bone marrow failure diseases
Xiao-Shen Sun, Xin Liu, Kai-Lin Xu, Allshine Chen, Witold B Rybka, Jeffrey J Pu
Xiao-Shen Sun, Xin Liu, Allshine Chen, Witold B Rybka, Jeffrey J Pu, Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA 17033, United States
Kai-Lin Xu, the Key Laboratory of Transplantation Immunity, Department of Hematology, Affiliated Hospital of Xuzhou Medical College, Xuzhou 221000, Jiangsu Province, China
Witold B Rybka, Jeffrey J Pu, Department of Medicine and Pathology, Penn State College of Medicine, Hershey, PA 17033, United States
Author contributions: Pu JJ outlined and designed the review; Sun XS and Chen A wrote the manuscript and generated the table and figure; Liu X and Pu JJ contributed to the writing of the manuscript; Liu X, Xu KL, Rybka WB and Pu JJ reviewed and edited the manuscript.
Supported by AA and MDSIF research grant to Pu JJ, No. 146818; American Cancer Society grant to Pu JJ, No. 124171-IRG-13-043-02; and a Pennsylvania State University College of Medicine research grant to Pu JJ.
Conflict-of-interest statement: The authors have no conflict–of-interest in this publication.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Jeffrey J Pu, MD, PhD, Penn State Hershey Cancer Institute, Penn State College of Medicine, H064, PO Box 850, 500 University Drive, Hershey, PA 17033, United States. jeffreypu@hmc.psu.edu
Telephone: +1-717-5314944 Fax: +1-717-5310647
Received: August 11, 2015
Peer-review started: August 13, 2015
First decision: September 17, 2015
Revised: December 12, 2015
Accepted: January 5, 2016
Article in press: January 7, 2016
Published online: February 6, 2016
Processing time: 169 Days and 17.7 Hours
Core Tip

Core tip: Stem cell transplantation is the only method can cure acquired bone marrow failure diseases (ABMFD). However, due to the high mortality rate of stem cell transplantation itself, this method is not usually used as the first line treatment for ABMFD. With the advance of current cellular therapy technology, it is becoming possible to cure ABMFD without significant treatment related complications.